Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep;12(9):1479–1484. doi: 10.4103/1673-5374.215260

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Neural Regeneration Research

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

PMC Copyright notice

Changes in p-CAMK4, CAMKK1 and CALM protein expression levels under GS treatment.

(A–C) p-CAMK4, CAMKK1 and CALM protein expression, respectively, in the hippocampus of AD rats under GS treatment. Results are the gray value ratio of target proteins and β-actin. *P < 0.01, vs. sham group; #P < 0.01, ##P < 0.05, vs. AD group. Data are shown as the mean ± SD (n = 3, one-way analysis of variance and the least significant difference test). Sham: Sham-operated group (injected with normal saline, normal feed); AD: Alzheimer's disease group (intraperitoneal injection of D-galactose in combination with bilateral hippocampal injection of amyloid-β peptide (25–35), 0.5% sodium carboxymethyl cellulose); GS: genistein group (90 mg/kg GS); EV: estradiol valerate group (0.3 mg/kg EV). CALM: calmodulin; CAMKK1: calmodulin dependent protein kinase kinase 1; CAMK4: calcium/calmodulin dependent protein kinase IV.